Kidney Diseases最新文献

{"title":"Association between Acute Kidney Injury and Dementia: A Multi-Database Cohort Study.","authors":"Zhixin Guo, Caoxiang She, Yaduan Lin, Shiyu Zhou, Fan Luo, Lisha Cao, Yinfang Sun, Ruixuan Chen, Mingzhen Pang, Xian Shao, Sheng Nie","doi":"10.1159/000545963","DOIUrl":"10.1159/000545963","url":null,"abstract":"<p><strong>Introduction: </strong>With the aging of population, dementia has emerged as a major public health concern, imposing a heavy society burden. However, the relationship between acute kidney injury (AKI) and the risk of dementia remains uncertain.</p><p><strong>Methods: </strong>A total of 1,256,756 participants from the China Renal Data System (CRDS) database and 492,250 individuals from the UK biobank (UKB) dataset were included in the study. The study investigated the associations between AKI and the onset of dementia. The exposure of interest was AKI. The outcome in both the CRDS and UKB cohorts was dementia.</p><p><strong>Results: </strong>The CRDS cohort identified 7,878 patients with new-onset dementia, while the UKB recorded 9,926 dementia cases during follow-up. AKI showed a significant association with the risk of dementia in both the CRDS (adjusted HR: 1.22; 95% confidence interval [CI]: 1.13-1.30, <i>p</i> < 0.001) and UKB cohorts (adjusted HR: 1.64; 95% CI 1.29-1.98, <i>p</i> = 0.005). In the CRDS cohort, patients with more severe AKI (stage 2-3 AKI) (aHR: 1.25; 95% CI 1.09-1.42, <i>p</i> = 0.008) exhibited a higher adjusted HR for dementia compared to those at AKI stage 1 (aHR: 1.21; 95% CI 1.11-1.30, <i>p</i> < 0.001). The association between AKI and dementia remained consistent across different subgroups in both cohorts.</p><p><strong>Conclusion: </strong>Our findings demonstrated that AKI was associated with an elevated risk of all-cause dementia. Consequently, patients with history of AKI episodes necessitate vigilant monitoring for prevention of dementia.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"365-376"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of P2Y2 Attenuates Cisplatin-Induced AKI via Reduced Oxidative Stress, Inflammation and Cell Death.","authors":"Fengyu Su, Ting Wang, Xiuli Lin, Yang Du, Yan Guo, Weidong Cao, Yaqiong Shang, Anning Zhou, Songming Huang, Zhanjun Jia, Yue Zhang, Aihua Zhang, Xiaomei Tang, Shuang Chen","doi":"10.1159/000546033","DOIUrl":"10.1159/000546033","url":null,"abstract":"<p><strong>Introduction: </strong>Purinergic signaling has been recognized as important extracellular regulator in multiple physiological and pathophysiological conditions. Adenosine triphosphate-purinergic receptor P2Y2 signaling pathway is associated with glomerular nephritis (GN), diabetic nephropathy (DN), and chronic kidney disease. Recently, there has been evidence that global knockout of P2Y2 exacerbated bilateral ischemic reperfusion-induced acute kidney injury (AKI). However, its role in cisplatin-induced AKI (CIA) remains unknown. Cisplatin is a platinum-containing antineoplastic drug widely used in variety of solid malignant tumors. Nephrotoxicity is one of the major serious side effect that limit its clinical use. In the present study, we investigated whether inhibition of P2Y2 has an effect on CIA.</p><p><strong>Methods: </strong>We used AR-C118925 (AR-C), a selective antagonist of P2Y2, and gene transfection for interruption of the P2Y2 pathway. Mice were pretreated with AR-C (10 mg/kg/day) and then challenged with cisplatin at a dose of 20 mg/kg. Seventy-two hours after cisplatin administration, all mice developed kidney failure. Knockdown and overexpression of P2Y2 in mice and mouse proximal tubular cells (mPTCs) were employed to validate that ARC acts through P2Y2 receptor.</p><p><strong>Results: </strong>AR-C markedly ameliorated cisplatin-induced nephrotoxicity evidenced by improved renal function, renal morphology, and tubular injury marker expression. Further analysis of the mechanism revealed that AR-C significantly reduced kidney oxidative stress, inflammation, apoptosis, and necroptosis. Consistently, AR-C protects mPTCs from injury caused by cisplatin. To verify that AR-C acts through the P2Y2 receptor, we knocked down P2Y2 in mice or in mPTC cells. Both showed beneficial effects, while overexpression of P2Y2 promotes cisplatin-induced cell death.</p><p><strong>Conclusion: </strong>Taken together, our study, for the first time revealed that P2Y2 plays an important role in CIA by regulating oxidative stress, inflammation, apoptosis, and necroptosis and its inhibitor, AR-C, is a potential drug for treating CIA.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"416-438"},"PeriodicalIF":3.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Adherence and the Serum Phosphate, Calcium, and Intact Parathyroid Hormone Control in Peritoneal Dialysis Patients: Effectiveness of Smart PD Care Program.","authors":"Yan Yang, Li Fan, Binbin Lu, Yuanhui Qiu, Zhenhu Chen, Jie Li, Yilin Zeng, Lili Deng, Zhiming Ye, Xueqing Yu","doi":"10.1159/000545964","DOIUrl":"10.1159/000545964","url":null,"abstract":"<p><strong>Introduction: </strong>Patient adherence is important for long-term outcomes of peritoneal dialysis (PD). Artificial intelligence is a good tool to manage patients. However, there are limited data regarding its impact on the patient adherence and the effect of patient adherence on serum phosphate, calcium, and intact parathyroid hormone (iPTH) control in PD patients.</p><p><strong>Methods: </strong>This was a single-center, prospective cohort study including PD patients in Guangdong Provincial People's Hospital. Adult patients (age ≥18 years) who were included in the smart PD care program from September 1, 2020, to April 31, 2023, were enrolled. Patient adherence was assessed using the patient-reported daily PD prescription data and calculated as the total days with PD ultrafiltration reported divided by the total days of follow-up. Good adherence was defined as the reporting rate ≥80%. The primary outcome was serum phosphate, calcium, and iPTH values achieved the treatment targets at 12-month follow-up. Unadjusted and adjusted generalized estimating equations were used to evaluate the association of patient adherence with the serum phosphorus, serum calcium, and iPTH control.</p><p><strong>Results: </strong>A total of 267 patients were included in this study. The mean age of the whole cohort was 43.3 ± 12.8 years, 130 (48.7%) were females, and 52 (19.5%) had diabetes. Patient adherence improved after being included in the smart PD care program and the overall patient adherence during 12-month follow-up was 77.1% ± 26.4%, 93.0% ± 7.4%, and 50.9% ± 25.6% for the entire cohort, patients with good adherence, and those with poor adherence, respectively. Compared to patients with poor adherence, those with good adherence were associated with a better serum calcium (adjusted OR: 3.76; 95% CI: 2.67-5.30; <i>p</i> < 0.001) and iPTH control (adjusted OR: 2.20; 95% CI: 1.56-3.11; <i>p</i> < 0.001) but not for serum phosphorus control (adjusted OR: 1.31; 95% CI: 0.89-1.91; <i>p</i> = 0.17) after being adjusted for potential confounders. Results were similar when assessing the relationship between patient adherence and the longitudinal changes of serum calcium, iPTH, and phosphorus during follow-up.</p><p><strong>Conclusions: </strong>Smart PD care program was effective in improving patient adherence. Good patient adherence was associated with better serum calcium and iPTH control but not for phosphorus control in PD patients. Further studies should be done to evaluate the effect of the smart PD care program on long-term patient outcomes.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"356-364"},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Low-Density Lipoprotein Receptor-Related Protein-1 on Acute Kidney Injury and Renal Tubular Epithelial Triglyceride Accumulation.","authors":"Weiteng Wang, Jieyi Luo, Yingwen Chen, Huaban Liang, Zhilian Li, Yuanhan Chen, Jintao He, Xinling Liang","doi":"10.1159/000545851","DOIUrl":"10.1159/000545851","url":null,"abstract":"<p><strong>Introduction: </strong>Various types of acute kidney injury (AKI) are associated with triglyceride (TG) accumulation in renal tubular epithelial cells, but the role and mechanisms of TG accumulation in AKI remain unclear. This study aimed to explore the impact of low-density lipoprotein (LDL) receptor-related protein-1 (LRP1), a protein that mediates TG endocytosis, on ischemia-reperfusion injury (IRI)-induced AKI and TG accumulation in renal tubular epithelial cells.</p><p><strong>Methods: </strong>We established an IRI-induced AKI mouse model and assessed LRP1 expression by Western blot, RT-qPCR, and immunofluorescence. The LRP1 antagonist receptor-associated protein (RAP) was used to evaluate the effect of LRP1 on AKI and renal TG accumulation in the AKI mouse model. We applied a carbonyl cyanide 3-chlorophenylhydrazone (CCCP)-induced hypoxia-reoxygenation model to HK-2 cells in vitro. The effects of very low-density lipoproteins (VLDLs) and LRP1 silencing on TG levels, cell viability, and apoptosis in HK-2 cells were observed.</p><p><strong>Results: </strong>We observed significant TG accumulation in renal tissue during IRI-AKI, accompanied by upregulation of LRP1 in renal tubular epithelial cells. After intervention with the LRP1 antagonist RAP, AKI was significantly alleviated, and TG levels in renal tissue were notably reduced. However, in the in vitro model, although VLDL increased TG levels in HK-2 cells in both normal culture and hypoxia-reoxygenation conditions, it did not alleviate the decrease in cell viability induced by CCCP. In the absence of exogenous VLDL, silencing LRP1 still reduced CCCP-induced TG accumulation and cell apoptosis, although the reduction in TG levels was less pronounced compared to the presence of exogenous VLDL.</p><p><strong>Conclusion: </strong>Our study demonstrated that the increased expression of LRP1 on renal tubular epithelial cells contributes to IRI-induced AKI and TG accumulation. The injury effects of LRP1 on the renal tubules are independent of TG endocytosis. Targeting the inhibition of LRP1 may emerge as a novel therapeutic strategy for AKI.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"320-331"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12112978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease.","authors":"Junlan Yang, Zhiyuan Wei, Haifeng Ni, Qianqian Wu, Siqi Peng, Wen Shi, Xiaoxu Wang, Yan Yang, Jianan Jiang, Jingyuan Cao, Yao Wang, Liyuan Zhang, Aihua Zhang, Xiaoliang Zhang, Bin Wang","doi":"10.1159/000545604","DOIUrl":"10.1159/000545604","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of urinary myeloid bodies in Fabry disease patients and their correlation with renal involvement remains unclear.</p><p><strong>Methods: </strong>This single-center, retrospective study included 25 patients with Fabry disease and 27 controls. We analyzed 24-h urine samples for the presence of urinary myeloid bodies and evaluated clinical data, including serum creatinine, estimated glomerular filtration rate (eGFR), 24-h urinary protein levels, α-Gal A, and Lyso-GL-3. Seven Fabry patients underwent analysis of urine samples before and after 1 year of enzyme replacement therapy (ERT).</p><p><strong>Results: </strong>Urinary myeloid bodies were detected in 84% of Fabry patients (21 out of 25), with no significant gender differences. None of the healthy controls or patients with other renal disease patients had urinary myeloid bodies. Among the Fabry patients with myeloid bodies, 48% had no proteinuria, and 52% were in CKD1 stage G1. Furthermore, urinary myeloid bodies were detected in 4 patients under the age of 20, despite the absence of or only minimal proteinuria, and these patients all exhibited a substantial number of myeloid bodies. After 1 year of ERT, significant reductions in both the count (<i>p</i> = 0.043) and area ratio (<i>p</i> = 0.028) of myeloid bodies were observed.</p><p><strong>Conclusion: </strong>Urinary myeloid bodies are specific to Fabry disease and are associated with early renal injury, even in the absence of proteinuria. These findings suggest that urinary myeloid bodies may serve as a noninvasive biomarker for the early diagnosis of Fabry disease and for monitoring the efficacy of ERT.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"332-341"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Kidney Injury Molecule-1 and HAVCR1 Polymorphisms as Predictive Biomarkers in Chronic Kidney Disease.","authors":"Nachayada Chaiyagot, Atit Silsirivanit, Ubon Cha'on, Apinya Jusakul, Anchalee Techasen, Kanokwan Nahok, Angkor Chamdam, Sirirat Anutrakulchai, Worachart Lert-Itthiporn","doi":"10.1159/000545831","DOIUrl":"10.1159/000545831","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney injury molecule-1 (KIM-1), encoded by the Hepatitis A Virus Cellular Receptor 1 (<i>HAVCR1</i>) gene, plays a crucial role in kidney injury progression. Although serum and urinary KIM-1 levels are established biomarkers for kidney damage, the relationship between KIM-1 levels, <i>HAVCR1</i> gene polymorphism, and chronic kidney disease (CKD) stages remains unclear. This study aimed to investigate KIM-1 as a potential biomarker for CKD progression in the Thai population and explore its association with genetic polymorphisms in the <i>HAVCR1</i> gene.</p><p><strong>Methods: </strong>A total of 250 patients with CKD were recruited from Khon Kaen, Thailand. Serum and urinary KIM-1 levels were measured using an indirect enzyme-linked immunosorbent assay. Single-nucleotide polymorphism (SNP) genotyping was conducted using the TaqMan assay to assess the associations between KIM-1 levels, SNPs, and CKD progression. Statistical analyses were conducted to assess the correlations between estimated glomerular filtration rate (eGFR), KIM-1 levels, and SNPs.</p><p><strong>Results: </strong>Serum and urinary KIM-1 levels showed a significant negative correlation with eGFR, indicating higher KIM-1 levels in patients with more advanced CKD. However, the rs6555820 SNP in the <i>HAVCR1</i> gene did not show a significant association with KIM-1 levels or eGFR. Interestingly, a significant association between rs6555820 and gender was observed, implying a potential gender-dependent genetic impact.</p><p><strong>Conclusion: </strong>Serum and urinary KIM-1 levels have been found to be associated with CKD stages and eGFR, suggesting their potential as biomarkers for assessing CKD severity. However, no direct associations were observed between the SNP rs6555820 and KIM-1 levels or eGFR. Further research is required to elucidate the genetic mechanisms underlying CKD progression.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"342-355"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000544850","DOIUrl":"https://doi.org/10.1159/000544850","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000538106.].</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"194"},"PeriodicalIF":3.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in miRNA Biomarkers for Diagnosis and Prognosis of Focal Segmental Glomerulosclerosis.","authors":"Yufei Sun, Shuang Liu, Wan Ding, Chun Zhu, Gengru Jiang, Huilin Li","doi":"10.1159/000545240","DOIUrl":"10.1159/000545240","url":null,"abstract":"<p><strong>Background: </strong>Focal segmental glomerulosclerosis (FSGS) is an increasingly prevalent group of refractory glomerular diseases and a significant aetiology of end-stage renal disease. Podocyte injury and depletion significantly contribute to the pathogenesis and progression of FSGS. MicroRNAs (miRNAs) are noncoding RNAs that regulate the expression of specific genes in relevant cells, thereby playing crucial roles in the pathogenesis of FSGS. Many studies have shown that miRNAs can be secreted from cells into body fluids and that these miRNAs in the circulation are highly stable. The gold standard for FSGS diagnosis is kidney biopsy; however, the clinical heterogeneity of FSGS, along with variations in histology and nonspecific morphological features, can impact its diagnostic accuracy. Thus, the discovery of novel and efficacious biomarkers is crucial in facilitating the diagnosis of FSGS. In addition, the degree of kidney damage in patients with FSGS varies at different stages, necessitating individualized diagnosis and treatment approaches. Considering the side effects of glucocorticoids, determining whether a patient is steroid resistant is vital. Thus, ideal biomarkers should not only be specific and sensitive but also have the ability to accurately reflect the stage or prognosis of the disease to improve the treatment for patients.</p><p><strong>Summary: </strong>To date, numerous studies have shown that both urinary miRNAs and plasma miRNAs are potential biomarkers for FSGS. In addition, the identification of miRNA biomarkers specific for the FSGS disease state may provide new insights into the underlying pathological mechanism of FSGS.</p><p><strong>Key messages: </strong>Here we summarize the currently available miRNA biomarkers that could help us better understand the diagnosis, disease activity, prognosis, and clinical features of FSGS.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"283-291"},"PeriodicalIF":3.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering Intercellular Communication of the Immune Landscape within Autosomal Dominant Polycystic Kidney Disease Microenvironment at Single-Cell Resolution.","authors":"Fei Liu, Xiaoyi Li, Qiuyu Li, Jinglan Gu, Qi Shi, Jiayi Song, Na Jiao, Jianhua Mao","doi":"10.1159/000545663","DOIUrl":"10.1159/000545663","url":null,"abstract":"<p><strong>Introduction: </strong>Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that often leads to end-stage renal disease, with disease progression deeply influenced by the renal microenvironment. This study aims to unravel the critical cellular types and their intricate interactions within the ADPKD microenvironment.</p><p><strong>Methods: </strong>Leveraging single-cell transcriptome data from seven ADPKD and three healthy human kidney samples, we systematically dissected the cellular landscape of the ADPKD microenvironment. Our approach included CellChat for cell-cell communication analysis, VISION for pathway enrichment analysis, pySCENIC for regulon activity calculation, and Monocle V3 for pseudotime trajectory construction.</p><p><strong>Results: </strong>We identified nine major cell lineages, with a notable increase of mononuclear phagocytes (MNPs), T cells, and fibroblasts in the ADPKD microenvironment. These cells collectively orchestrated a distinctive microenvironment, marked by complex intercellular networks. Notably, a specific subset of macrophages exhibited an \"M2-like\" phenotype, which was driven by IL-10 signaling from M1-like macrophages and contributed to cyst cell proliferation. Immunosuppression was predominantly mediated by CD4+ T cells, activated by macrophages through immune checkpoint pathways, such as PDL1 signaling. The fibrotic expansion was a cumulative effect of fibroblast activation and proliferation, modulated by macrophages and cyst-lining epithelial cells.</p><p><strong>Conclusion: </strong>This comprehensive investigation provides valuable insights into the diverse landscapes of the ADPKD microenvironment at single-cell resolution, emphasizing MNPs, T cells, and fibroblasts. The study unveils complex interactions among these cell types, shedding light on an understanding of the immunological aspect of ADPKD and proposing potential therapeutic targets.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"302-318"},"PeriodicalIF":3.2,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Restless Legs Syndrome and Sleep Disturbance and 3-Year Mortality in Hemodialysis Patients.","authors":"Lanbo Teng, Huanan Li, Yingying Han, Tao Yuan, Chuhan Xu, Tao Tan, Wenxiu Chang","doi":"10.1159/000545008","DOIUrl":"10.1159/000545008","url":null,"abstract":"<p><strong>Introduction: </strong>Whether restless legs syndrome (RLS) and sleep disturbance (SD) in hemodialysis (HD) patients influence all-cause and cardiovascular mortality remains controversial. The aim of this study was to evaluate the association between RLS or SD and 3-year mortality in HD patients.</p><p><strong>Methods: </strong>A total of 301 patients who underwent HD were examined in April 2021 and were followed up for 3 years. The median follow-up time was 36.0 [33.3, 36.0] months. Fifty-four patients fulfilled the diagnosis of RLS (17.9%), 126 patients complained of SD (41.9%). Demographic parameters, clinical features, laboratory indices, and two questionnaires to assess the diagnosis of RLS and sleep status were collected. All-cause mortality and cardiovascular mortality in this population were evaluated. Cox regression analyses and Kaplan-Meier curves were performed to determine the effect of RLS or SD on 3-year mortality.</p><p><strong>Results: </strong>The RLS group reported that 29 patients (53.8%) exhibited concurrent symptoms of SD. The presence of RLS or SD alone did not significantly elevate the risk of all-cause mortality (<i>p</i> = 0.053 and <i>p</i> = 0.193). However, the coexistence of RLS and SD was identified as an independent risk factor for all-cause mortality (<i>p</i> = 0.011). Furthermore, the various combinations associated with RLS or SD were found to be independently correlated with the risk of cardiovascular death (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The combination of RLS and SD in HD patients is associated with an increased risk of cardiovascular and all-cause mortality, underscoring the clinical significance of this association.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"160-169"},"PeriodicalIF":3.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}